{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:36:48Z","timestamp":1778045808633,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this review is to discuss the existing literature regarding patients who have experienced seizures after administration of a bone density conservation agent (BDCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A comprehensive literature review was performed between September and October 2021 using the following keywords: osteoporosis\/drug therapy, seizures\/chemically induced, hypercalcemia, hypocalcemia, osteoporosis, seizure risk, osteoclast medication, seizures, bisphosphonates, risedronate, zoledronic acid, pamidronate, denosumab, Prolia, Xgeva, calcitonin, BDCAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>A total of 90 articles were identified, but only 6 articles met prespecified inclusion and exclusion criteria. These articles included 4 case reports, 1 case series, and 1 retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>Two case reports and 1 case series described the occurrence of seizures with the use of zoledronic acid. One case report described the occurrence of seizures with the use of alendronate, 1 retrospective cohort study with the use of denosumab, and 1 case report with the use of calcitonin. The articles displayed a variety of contributing factors that could have caused seizures including those with a prior history of seizures, calcium or vitamin D deficiency prior to starting therapy, a history of gastrectomy impairing glucose homeostasis, or concurrent infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While there is not a direct link to BDCA causing seizures, the hypocalcemic effect may be severe enough in some patients to precipitate a seizure. The correction of underlying conditions and electrolyte disturbances should be addressed before initiating a BDCA. Further studies are needed to better explore the relationship between BDCA and seizures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/87551225211070978","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T02:21:25Z","timestamp":1643250085000},"page":"119-126","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Seizures Associated With Bone Density Conservation Agents"],"prefix":"10.1177","volume":"38","author":[{"given":"Kuan","family":"Sturgill","sequence":"first","affiliation":[{"name":"Bon Secours Mercy Health St. Vincent Medical Center, Toledo, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0321-5608","authenticated-orcid":false,"given":"Justin P.","family":"Reinert","sequence":"additional","affiliation":[{"name":"Bon Secours Mercy Health St. Vincent Medical Center, Toledo, OH, USA"},{"name":"The Ben and Maytee Fisch College of Pharmacy, The University of Texas at Tyler, Tyler, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"bibr1-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1513724"},{"key":"bibr2-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05766.x"},{"issue":"5","key":"bibr3-87551225211070978","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1055\/s-0040-1714219","volume":"56","author":"Oliveira LG","year":"2021","journal-title":"Rev Bras Ortop"},{"key":"bibr4-87551225211070978","first-page":"1551","volume":"29","author":"Lumachi F","year":"2009","journal-title":"Anticancer Res"},{"issue":"5","key":"bibr5-87551225211070978","first-page":"496","volume":"9","author":"Feldenzer KL","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"bibr6-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2014.0207"},{"key":"bibr7-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1097\/TME.0000000000000093"},{"key":"bibr8-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1159\/000380960"},{"key":"bibr9-87551225211070978","unstructured":"Aclasta (zoledronic acid). Montreal, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; April 2017."},{"key":"bibr10-87551225211070978","unstructured":"ACH-alendronate. Montreal, Quebec, Canada: Accord Healthcare, Inc; December 2020."},{"key":"bibr11-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1001"},{"key":"bibr12-87551225211070978","unstructured":"Miacalcin injection (calcitonin-salmon). Charleston, SC: Alcami Corporation; May 2021."},{"key":"bibr13-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.041"},{"key":"bibr14-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026597816193"},{"key":"bibr15-87551225211070978","first-page":"741","volume-title":"Basic & Clinical Endocrinology","volume":"1997","author":"Strewler GJ"},{"key":"bibr16-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1177\/1759091415578050"},{"key":"bibr17-87551225211070978","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2016.12.1.21"},{"key":"bibr18-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0418"},{"key":"bibr19-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2007.0113"},{"key":"bibr20-87551225211070978","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2020-0234"},{"key":"bibr21-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1177\/014107680209501212"},{"key":"bibr22-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2004.08.012"},{"key":"bibr23-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5948254"},{"key":"bibr24-87551225211070978","doi-asserted-by":"publisher","DOI":"10.1177\/2042018811416271"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225211070978","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225211070978","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225211070978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:30:44Z","timestamp":1777602644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225211070978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1177\/87551225211070978"],"URL":"https:\/\/doi.org\/10.1177\/87551225211070978","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]}}}